







Claudin 7 mouse mAb(ABT161)

Catalog No	YP-Ab-15562
Isotype	IgG
Reactivity	Human;Mouse
Applications	IHC,WB
Gene Name	CLDN7 CEPTRL2 CPETRL2
Protein Name	Claudin 7
Immunogen	Synthesized peptide derived from human Claudin 7
Specificity	The antibody can specifically recognize human Claudin 7 protein. In western blotting of LnCap cell lysate, the antibody can label a 22KDa band corresponding to Claudin 7.
Formulation	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.07% sodium azide.
Source	Monoclonal, Mouse/IgG2b, Kappa
Purification	The antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen.
Dilution	IHC-p 1:100-500, IF 1:100-500
Concentration	1 mg/ml
Purity	≥90%
Storage Stability	-20°C/1 year
Synonyms	Claudin-7 (CLDN-7)
Observed Band	
Cell Pathway	Cell membrane ; Multi-pass membrane protein . Basolateral cell membrane . Cell junction, tight junction . Co-localizes with EPCAM at the basolateral cell membrane and tight junction
Tissue Specificity	Expressed in kidney lung and prostets Joseph 1 access to be prodominant
	Expressed in kidney, lung and prostate. Isoform 1 seems to be predominant, except in some normal prostate samples, where isoform 2 is the major form. Down-regulated in breast cancers, including ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS) and invasive ductal carcinoma (IDC) (at protein level), as well as in several cancer cell lines. Loss of expression correlates with histological grade, occurring predominantly in high-grade lesions.
Function	except in some normal prostate samples, where isoform 2 is the major form. Down-regulated in breast cancers, including ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS) and invasive ductal carcinoma (IDC) (at protein level), as well as in several cancer cell lines. Loss of expression correlates with
Function Background	except in some normal prostate samples, where isoform 2 is the major form. Down-regulated in breast cancers, including ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS) and invasive ductal carcinoma (IDC) (at protein level), as well as in several cancer cell lines. Loss of expression correlates with
	except in some normal prostate samples, where isoform 2 is the major form. Down-regulated in breast cancers, including ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS) and invasive ductal carcinoma (IDC) (at protein level), as well as in several cancer cell lines. Loss of expression correlates with



UpingBio technology Co.,Ltd

€ Tel: 400-999-8863 **■** Email:3631691544@qq.com



Usage suggestions

This product can be used in immunological reaction related experiments. For more information, please consult technical personnel.

Products Images